JP2025121986A5 - - Google Patents

Info

Publication number
JP2025121986A5
JP2025121986A5 JP2025077691A JP2025077691A JP2025121986A5 JP 2025121986 A5 JP2025121986 A5 JP 2025121986A5 JP 2025077691 A JP2025077691 A JP 2025077691A JP 2025077691 A JP2025077691 A JP 2025077691A JP 2025121986 A5 JP2025121986 A5 JP 2025121986A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
polypeptide
collagen
linker
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025077691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025121986A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/070113 external-priority patent/WO2020247974A1/en
Application filed filed Critical
Publication of JP2025121986A publication Critical patent/JP2025121986A/ja
Publication of JP2025121986A5 publication Critical patent/JP2025121986A5/ja
Pending legal-status Critical Current

Links

JP2025077691A 2019-06-03 2025-05-08 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 Pending JP2025121986A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962856468P 2019-06-03 2019-06-03
US62/856,468 2019-06-03
PCT/US2020/070113 WO2020247974A1 (en) 2019-06-03 2020-06-03 Methods and compositions for treating cancer with collagen binding drug carriers
JP2021571671A JP7680375B2 (ja) 2019-06-03 2020-06-03 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021571671A Division JP7680375B2 (ja) 2019-06-03 2020-06-03 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2025121986A JP2025121986A (ja) 2025-08-20
JP2025121986A5 true JP2025121986A5 (cg-RX-API-DMAC7.html) 2025-12-17

Family

ID=73652058

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021571671A Active JP7680375B2 (ja) 2019-06-03 2020-06-03 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物
JP2025077691A Pending JP2025121986A (ja) 2019-06-03 2025-05-08 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021571671A Active JP7680375B2 (ja) 2019-06-03 2020-06-03 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物

Country Status (9)

Country Link
US (1) US20220298225A1 (cg-RX-API-DMAC7.html)
EP (1) EP3976111A4 (cg-RX-API-DMAC7.html)
JP (2) JP7680375B2 (cg-RX-API-DMAC7.html)
CN (1) CN114173822B (cg-RX-API-DMAC7.html)
AU (1) AU2020289485A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021024438A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144535A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021014932A (cg-RX-API-DMAC7.html)
WO (1) WO2020247974A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206355A (zh) 2019-06-03 2022-03-18 芝加哥大学 用靶向癌症的佐剂治疗癌症的方法和组合物
WO2024177006A1 (ja) * 2023-02-20 2024-08-29 国立大学法人大阪大学 細胞にタンパク質付着性を付与する細胞デザイナー分子
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles
US12667578B2 (en) 2024-07-25 2026-06-30 Visionary Assets, Llc Cryogenic process for making cannabinoid nanoparticles and compositions made thereby

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
RU2579977C2 (ru) * 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2012112690A2 (en) * 2011-02-16 2012-08-23 Fabius Biotechnology Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
WO2015061752A1 (en) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
DK3186284T3 (da) * 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
US10420820B2 (en) * 2014-09-29 2019-09-24 Counterpoint Biomedia LLC Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
KR20210080460A (ko) * 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질

Similar Documents

Publication Publication Date Title
US20240156894A1 (en) Stable antibody-drug conjugate, preparation method therefor, and use thereof
Li et al. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL
US7033572B2 (en) Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
US8920777B2 (en) Toxins and radionuclides coupled to IGF-1 receptor ligands for treatment of cancer
Curnis et al. NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors
US11697675B2 (en) EPHA3 and multi-valent targeting of tumors
JP2021502810A5 (cg-RX-API-DMAC7.html)
JP2017509594A5 (cg-RX-API-DMAC7.html)
US20110262466A1 (en) Compositions containing thrombomodulin domains and uses thereof
CA2230479A1 (en) Transcytosis vehicles and enhancers for drug delivery
HRP20030192A2 (en) Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target specific prodrug
JP2022535816A5 (cg-RX-API-DMAC7.html)
JP2024517871A5 (cg-RX-API-DMAC7.html)
JP2022520596A5 (cg-RX-API-DMAC7.html)
AU4104700A (en) Antibody and chemokine constructs that are directed to CCR5, and their use for treating autoimmune diseases
Corti Strategies for improving the anti-neoplastic activity of TNF by tumor targeting
She et al. Snoopligase-catalyzed molecular glue enables efficient generation of hyperoligomerized TRAIL variant with enhanced antitumor effect
Jarvinen et al. Systemically administered, target-specific therapeutic recombinant proteins and nanoparticles for regenerative medicine
US11952402B2 (en) Fusion protein containing trail and IgG binding domain and the uses thereof
JP2017095417A (ja) 抗癌剤
Liu et al. Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli
US20210179673A1 (en) Methods and materials for treating cancer
WO2017147820A1 (zh) 双重标靶药物载体
US20250382360A1 (en) Anti-VEGF Single Chain Variable Fusion Protein (RNAT82)
US20250381288A1 (en) Anti-VEGF Single Chain Variable Fusion Protein (RNAT92)